

SGLT2 Inhibitors Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

<https://marketpublishers.com/r/SBE52238765CEN.html>

Date: September 2025

Pages: 87

Price: US\$ 3,200.00 (Single User License)

ID: SBE52238765CEN

Abstracts

SGLT2 Inhibitors Market Summary

The SGLT2 Inhibitors market is a critical segment within the global pharmaceutical industry, offering oral antidiabetic drugs that inhibit sodium-glucose cotransporter-2 to manage type 2 diabetes by promoting glucose excretion in urine, reducing HbA1c by 0.5–1.0% within 12 weeks. Beyond glycemic control, these inhibitors demonstrate cardiovascular and renal protective effects, lowering heart failure hospitalizations by 30% and slowing chronic kidney disease (CKD) progression by 40%, per landmark trials. This market is characterized by its precision in targeting metabolic pathways, with once-daily dosing, minimal hypoglycemia risk (under 2%), and compatibility with combination therapies like metformin or DPP-4 inhibitors. Innovations include fixed-dose combos and extended indications for non-diabetic CKD and heart failure, broadening therapeutic scope. As global diabetes prevalence exceeds 500 million and healthcare systems prioritize outcomes-based care, SGLT2 inhibitors align with value-based reimbursement models, integrating with digital health apps for real-time glucose monitoring. The global SGLT2 Inhibitors market is estimated to reach a valuation of approximately USD 13–20 billion in 2025, with compound annual growth rates projected in the range of 4.0%–9.0% through 2030. Growth is driven by rising diabetes incidence, expanded label approvals for cardiovascular and renal indications, and increasing adoption in emerging markets with improving healthcare access, positioning SGLT2 inhibitors as a cornerstone of cardiometabolic care.

Distribution Channel Analysis and Market Segmentation

Hospital Pharmacies Hospital pharmacies dominate for initiating SGLT2 therapy in acute

settings, particularly for type 2 diabetes patients with cardiovascular comorbidities, ensuring compliance with formularies like JNC8 for heart failure. These outlets leverage electronic prescribing systems for seamless integration with hospital EHRs. This segment is expected to expand at annual growth rates of 4.5%–8%, driven by inpatient initiations for CKD and heart failure under cardiologist oversight, with 70% of prescriptions tied to discharge plans. Trends include bundled dispensing with patient education apps, improving adherence by 25%, and formulary expansions in teaching hospitals, particularly in urban centers with high diabetes burdens.

Retail Pharmacies Retail pharmacies serve chronic patients managing diabetes outpatient, offering branded and generic SGLT2 inhibitors with counseling for lifestyle integration. This channel anticipates 4%–7.5% annual growth, fueled by chain pharmacies like Walgreens and Boots expanding diabetes care aisles. Developments include loyalty programs offering 10% discounts on refills and telepharmacy services for rural access, with QR-coded packaging linking to dosing reminders, boosting compliance by 20%.

Online Pharmacies Online pharmacies, such as PillPack and 1mg, cater to tech-savvy patients with subscription refills and home delivery, particularly for Jardiance and Farxiga. This segment projects 5.5%–9% growth, supported by e-commerce penetration in emerging markets and direct-to-consumer campaigns. Trends encompass AI-driven chatbots for side effect queries and blockchain-secured prescription verification, reducing counterfeit risks by 30%.

Others Other channels, including specialty clinics and mail-order services, focus on high-risk patients with CKD or heart failure, growing at 3%–6% annually. Innovations include automated refill systems tied to CGM data, enhancing precision dosing.

By Indication

Type 2 Diabetes Type 2 diabetes remains the core indication, with SGLT2 inhibitors reducing fasting glucose by 20–30 mg/dL, growing at 4%–7%. Trends include combo therapies with GLP-1 agonists for 1.5% HbA1c drops.

Cardiovascular Cardiovascular indications, particularly heart failure with reduced ejection fraction, grow at 5%–8%, with empagliflozin cutting mortality by 20%. Trends: expanded use in non-diabetic patients.

Chronic Kidney Disease (CKD) CKD indications, slowing eGFR decline by 4

mL/min/year, project 5.5%–9% growth. Innovations: trials for pediatric CKD.

Others Emerging indications like obesity management grow at 3%–6%, with trials exploring metabolic syndrome applications.

By Product

Jardiance (empagliflozin) Jardiance leads with \$7B sales, growing 4.5%–8%, with heart failure approvals driving 30% prescription growth.

Farxiga (dapagliflozin) Farxiga, with CKD focus, grows at 5%–8.5%, with generics looming in 2026.

Invokana (canagliflozin) Invokana grows at 3.5%–7%, with renal trials expanding use.

Inpefa (sotagliflozin) Inpefa, targeting dual SGLT1/2, projects 5%–9% growth.

Qtern (dapagliflozin/saxagliptin) Qtern's combo grows at 4%–7.5%, with DPP-4 synergy.

Other SGLT2 Inhibitors Pipeline drugs grow at 3%–6%, with novel formulations emerging.

Regional Market Distribution and Geographic Trends

Asia-Pacific: 5%–9% growth annually, led by India's 100M diabetic population and China's formulary inclusions, with Japan focusing on elderly CKD care.

North America: 4%–7.5% growth, driven by U.S. Medicare expansions and Canada's heart failure programs.

Europe: 3.5%–6.5% growth, with Germany's diabetes clinics and UK's NHS prioritizing Farxiga.

Latin America: 4.5%–8% growth, led by Brazil's SUS formulary and Mexico's private pharmacies.

Middle East & Africa: 4%–7% growth, with UAE's diabetes hubs and South Africa's CKD focus.

Key Market Players and Competitive Landscape

AstraZeneca: Farxiga generates \$5B, with 25% market share via CKD trials.

Boehringer Ingelheim: Jardiance leads with €4B sales, partnering with Lilly for combos.

Eli Lilly: Co-markets Jardiance, with \$10B diabetes portfolio.

Merck: Expands via CKD research, with \$50B revenue backing.

Johnson & Johnson: Invokana targets renal niches, with \$80B scale.

Lexicon Pharmaceuticals: Inpefa innovator, with \$1B pipeline.

Bristol-Myers Squibb: Early SGLT2 pioneer, shifting to generics.

Glenmark Pharmaceuticals: Indian generics, 20% cost advantage.

TheracosBio: Pipeline for novel inhibitors, with VC-backed trials.

Industry Value Chain Analysis The SGLT2 Inhibitors value chain spans API synthesis, clinical validation, distribution, and patient integration, with value in branded efficacy.

Raw Materials and Upstream Supply APIs like empagliflozin sourced from chiral intermediates, with AstraZeneca securing 5,000 tons annually via GMP suppliers.

Production and Processing Tableting and coating in FDA-approved plants ensure 99.9% purity, with Lilly scaling 1B doses yearly.

Distribution and Logistics Cold-chain for combos, with Merck's hubs ensuring 95% on-time delivery.

Downstream Processing and Application Integration

Hospital Pharmacies: EHR-linked dispensing.

Retail Pharmacies: Counseling for adherence.

Online Pharmacies: Subscription refills. Downstream yields 30% margins via patient apps.

End-User Industries Hospitals and patients capture value through 50% readmission cuts, with payers rebating for outcomes.

Market Opportunities and Challenges

Opportunities Asia-Pacific's diabetes surge drives generics, with Glenmark cutting costs 20%. Europe's CKD approvals expand Farxiga use, while Latin America's private pharmacies boost access. Digital CGM integrations enhance adherence, and non-diabetic indications unlock new niches.

Challenges Patent cliffs by 2026 risk 30% revenue drops. High costs—\$500/month—limit emerging market penetration. Side effect concerns like ketoacidosis (1% incidence) require monitoring, while formulary restrictions in public systems cap growth. Biosimilar competition pressures pricing.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 SGLT2 Inhibitors Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST SGLT2 INHIBITORS MARKET IN NORTH AMERICA (2020-2030)

- 8.1 SGLT2 Inhibitors Market Size
- 8.2 SGLT2 Inhibitors Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 SGLT2 Inhibitors Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST SGLT2 INHIBITORS MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 SGLT2 Inhibitors Market Size
- 9.2 SGLT2 Inhibitors Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 SGLT2 Inhibitors Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina
 - 9.5.3 Chile
 - 9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST SGLT2 INHIBITORS MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 SGLT2 Inhibitors Market Size
- 10.2 SGLT2 Inhibitors Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 SGLT2 Inhibitors Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST SGLT2 INHIBITORS MARKET IN EUROPE (2020-2030)

- 11.1 SGLT2 Inhibitors Market Size
- 11.2 SGLT2 Inhibitors Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 SGLT2 Inhibitors Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST SGLT2 INHIBITORS MARKET IN MEA (2020-2030)

- 12.1 SGLT2 Inhibitors Market Size
- 12.2 SGLT2 Inhibitors Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 SGLT2 Inhibitors Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL SGLT2 INHIBITORS MARKET (2020-2025)

- 13.1 SGLT2 Inhibitors Market Size
- 13.2 SGLT2 Inhibitors Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 SGLT2 Inhibitors Market Size by Type

CHAPTER 14 GLOBAL SGLT2 INHIBITORS MARKET FORECAST (2025-2030)

- 14.1 SGLT2 Inhibitors Market Size Forecast
- 14.2 SGLT2 Inhibitors Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 SGLT2 Inhibitors Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 AstraZeneca
 - 15.1.1 Company Profile
 - 15.1.2 Main Business and SGLT2 Inhibitors Information
 - 15.1.3 SWOT Analysis of AstraZeneca
 - 15.1.4 AstraZeneca SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Boehringer Ingelheim
 - 15.2.1 Company Profile
 - 15.2.2 Main Business and SGLT2 Inhibitors Information
 - 15.2.3 SWOT Analysis of Boehringer Ingelheim
 - 15.2.4 Boehringer Ingelheim SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Eli Lilly
 - 15.3.1 Company Profile
 - 15.3.2 Main Business and SGLT2 Inhibitors Information
 - 15.3.3 SWOT Analysis of Eli Lilly
 - 15.3.4 Eli Lilly SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Merck
 - 15.4.1 Company Profile
 - 15.4.2 Main Business and SGLT2 Inhibitors Information
 - 15.4.3 SWOT Analysis of Merck
 - 15.4.4 Merck SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Johnson & Johnson
 - 15.5.1 Company Profile

15.5.2 Main Business and SGLT2 Inhibitors Information

15.5.3 SWOT Analysis of Johnson & Johnson

15.5.4 Johnson & Johnson SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)

15.6 Lexicon Pharmaceuticals

15.6.1 Company Profile

15.6.2 Main Business and SGLT2 Inhibitors Information

15.6.3 SWOT Analysis of Lexicon Pharmaceuticals

15.6.4 Lexicon Pharmaceuticals SGLT2 Inhibitors Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

- Table Abbreviation and Acronyms
- Table Research Scope of SGLT2 Inhibitors Report
- Table Data Sources of SGLT2 Inhibitors Report
- Table Major Assumptions of SGLT2 Inhibitors Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure SGLT2 Inhibitors Picture
- Table SGLT2 Inhibitors Classification
- Table SGLT2 Inhibitors Applications
- Table Drivers of SGLT2 Inhibitors Market
- Table Restraints of SGLT2 Inhibitors Market
- Table Opportunities of SGLT2 Inhibitors Market
- Table Threats of SGLT2 Inhibitors Market
- Table COVID-19 Impact for SGLT2 Inhibitors Market
- Table Raw Materials Suppliers
- Table Different Production Methods of SGLT2 Inhibitors
- Table Cost Structure Analysis of SGLT2 Inhibitors
- Table Key End Users
- Table Latest News of SGLT2 Inhibitors Market
- Table Merger and Acquisition
- Table Planned/Future Project of SGLT2 Inhibitors Market
- Table Policy of SGLT2 Inhibitors Market
- Table 2020-2030 North America SGLT2 Inhibitors Market Size
- Figure 2020-2030 North America SGLT2 Inhibitors Market Size and CAGR
- Table 2020-2030 North America SGLT2 Inhibitors Market Size by Application
- Table 2020-2025 North America SGLT2 Inhibitors Key Players Revenue
- Table 2020-2025 North America SGLT2 Inhibitors Key Players Market Share
- Table 2020-2030 North America SGLT2 Inhibitors Market Size by Type
- Table 2020-2030 United States SGLT2 Inhibitors Market Size
- Table 2020-2030 Canada SGLT2 Inhibitors Market Size
- Table 2020-2030 Mexico SGLT2 Inhibitors Market Size
- Table 2020-2030 South America SGLT2 Inhibitors Market Size
- Figure 2020-2030 South America SGLT2 Inhibitors Market Size and CAGR
- Table 2020-2030 South America SGLT2 Inhibitors Market Size by Application
- Table 2020-2025 South America SGLT2 Inhibitors Key Players Revenue
- Table 2020-2025 South America SGLT2 Inhibitors Key Players Market Share

Table 2020-2030 South America SGLT2 Inhibitors Market Size by Type

Table 2020-2030 Brazil SGLT2 Inhibitors Market Size

Table 2020-2030 Argentina SGLT2 Inhibitors Market Size

Table 2020-2030 Chile SGLT2 Inhibitors Market Size

Table 2020-2030 Peru SGLT2 Inhibitors Market Size

Table 2020-2030 Asia & Pacific SGLT2 Inhibitors Market Size

Figure 2020-2030 Asia & Pacific SGLT2 Inhibitors Market Size and CAGR

Table 2020-2030 Asia & Pacific SGLT2 Inhibitors Market Size by Application

Table 2020-2025 Asia & Pacific SGLT2 Inhibitors Key Players Revenue

Table 2020-2025 Asia & Pacific SGLT2 Inhibitors Key Players Market Share

Table 2020-2030 Asia & Pacific SGLT2 Inhibitors Market Size by Type

Table 2020-2030 China SGLT2 Inhibitors Market Size

Table 2020-2030 India SGLT2 Inhibitors Market Size

Table 2020-2030 Japan SGLT2 Inhibitors Market Size

Table 2020-2030 South Korea SGLT2 Inhibitors Market Size

Table 2020-2030 Southeast Asia SGLT2 Inhibitors Market Size

Table 2020-2030 Australia SGLT2 Inhibitors Market Size

Table 2020-2030 Europe SGLT2 Inhibitors Market Size

Figure 2020-2030 Europe SGLT2 Inhibitors Market Size and CAGR

Table 2020-2030 Europe SGLT2 Inhibitors Market Size by Application

Table 2020-2025 Europe SGLT2 Inhibitors Key Players Revenue

Table 2020-2025 Europe SGLT2 Inhibitors Key Players Market Share

Table 2020-2030 Europe SGLT2 Inhibitors Market Size by Type

Table 2020-2030 Germany SGLT2 Inhibitors Market Size

Table 2020-2030 France SGLT2 Inhibitors Market Size

Table 2020-2030 United Kingdom SGLT2 Inhibitors Market Size

Table 2020-2030 Italy SGLT2 Inhibitors Market Size

Table 2020-2030 Spain SGLT2 Inhibitors Market Size

Table 2020-2030 Belgium SGLT2 Inhibitors Market Size

Table 2020-2030 Netherlands SGLT2 Inhibitors Market Size

Table 2020-2030 Austria SGLT2 Inhibitors Market Size

Table 2020-2030 Poland SGLT2 Inhibitors Market Size

Table 2020-2030 Russia SGLT2 Inhibitors Market Size

Table 2020-2030 MEA SGLT2 Inhibitors Market Size

Figure 2020-2030 MEA SGLT2 Inhibitors Market Size and CAGR

Table 2020-2030 MEA SGLT2 Inhibitors Market Size by Application

Table 2020-2025 MEA SGLT2 Inhibitors Key Players Revenue

Table 2020-2025 MEA SGLT2 Inhibitors Key Players Market Share

Table 2020-2030 MEA SGLT2 Inhibitors Market Size by Type

Table 2020-2030 Egypt SGLT2 Inhibitors Market Size
Table 2020-2030 Israel SGLT2 Inhibitors Market Size
Table 2020-2030 South Africa SGLT2 Inhibitors Market Size
Table 2020-2030 Gulf Cooperation Council Countries SGLT2 Inhibitors Market Size
Table 2020-2030 Turkey SGLT2 Inhibitors Market Size
Table 2020-2025 Global SGLT2 Inhibitors Market Size by Region
Table 2020-2025 Global SGLT2 Inhibitors Market Size Share by Region
Table 2020-2025 Global SGLT2 Inhibitors Market Size by Application
Table 2020-2025 Global SGLT2 Inhibitors Market Share by Application
Table 2020-2025 Global SGLT2 Inhibitors Key Vendors Revenue
Figure 2020-2025 Global SGLT2 Inhibitors Market Size and Growth Rate
Table 2020-2025 Global SGLT2 Inhibitors Key Vendors Market Share
Table 2020-2025 Global SGLT2 Inhibitors Market Size by Type
Table 2020-2025 Global SGLT2 Inhibitors Market Share by Type
Table 2025-2030 Global SGLT2 Inhibitors Market Size by Region
Table 2025-2030 Global SGLT2 Inhibitors Market Size Share by Region
Table 2025-2030 Global SGLT2 Inhibitors Market Size by Application
Table 2025-2030 Global SGLT2 Inhibitors Market Share by Application
Table 2025-2030 Global SGLT2 Inhibitors Key Vendors Revenue
Figure 2025-2030 Global SGLT2 Inhibitors Market Size and Growth Rate
Table 2025-2030 Global SGLT2 Inhibitors Key Vendors Market Share
Table 2025-2030 Global SGLT2 Inhibitors Market Size by Type
Table 2025-2030 SGLT2 Inhibitors Global Market Share by Type
Table AstraZeneca Information
Table SWOT Analysis of AstraZeneca
Table 2020-2025 AstraZeneca SGLT2 Inhibitors Revenue Gross Profit Margin
Figure 2020-2025 AstraZeneca SGLT2 Inhibitors Revenue and Growth Rate
Figure 2020-2025 AstraZeneca SGLT2 Inhibitors Market Share
Table Boehringer Ingelheim Information
Table SWOT Analysis of Boehringer Ingelheim
Table 2020-2025 Boehringer Ingelheim SGLT2 Inhibitors Revenue Gross Profit Margin
Figure 2020-2025 Boehringer Ingelheim SGLT2 Inhibitors Revenue and Growth Rate
Figure 2020-2025 Boehringer Ingelheim SGLT2 Inhibitors Market Share
Table Eli Lilly Information
Table SWOT Analysis of Eli Lilly
Table 2020-2025 Eli Lilly SGLT2 Inhibitors Revenue Gross Profit Margin
Figure 2020-2025 Eli Lilly SGLT2 Inhibitors Revenue and Growth Rate
Figure 2020-2025 Eli Lilly SGLT2 Inhibitors Market Share
Table Merck Information

Table SWOT Analysis of Merck

Table 2020-2025 Merck SGLT2 Inhibitors Revenue Gross Profit Margin

Figure 2020-2025 Merck SGLT2 Inhibitors Revenue and Growth Rate

Figure 2020-2025 Merck SGLT2 Inhibitors Market Share

Table Johnson & Johnson Information

Table SWOT Analysis of Johnson & Johnson

Table 2020-2025 Johnson & Johnson SGLT2 Inhibitors Revenue Gross Profit Margin

Figure 2020-2025 Johnson & Johnson SGLT2 Inhibitors Revenue and Growth Rate

Figure 2020-2025 Johnson & Johnson SGLT2 Inhibitors Market Share

Table Lexicon Pharmaceuticals Information

Table SWOT Analysis of Lexicon Pharmaceuticals

Table 2020-2025 Lexicon Pharmaceuticals SGLT2 Inhibitors Revenue Gross Profit Margin

Figure 2020-2025 Lexicon Pharmaceuticals SGLT2 Inhibitors Revenue and Growth Rate

Figure 2020-2025 Lexicon Pharmaceuticals SGLT2 Inhibitors Market Share

.....

I would like to order

Product name: SGLT2 Inhibitors Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: <https://marketpublishers.com/r/SBE52238765CEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBE52238765CEN.html>